Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Ana Martins; Sofia Pimenta; Daniela Oliveira; Rafaela Nicolau; Alexandra Bernardo; Teresa Martins Rocha; Lúcia Costa; Miguel Bernardes;

Seguridad de terapias biológicas y sintéticas dirigidas en pacientes con enfermedades inmunomediadas: datos del registro BIOBADAGUAY Paloma de Abreu; Sonia Cabrera; Darwin Cordovilla; Lourdes Román; Cristina Brunengo; Patricia Melgarejo; Macarena Soto; Vannia Valinotti; Angelica Amarilla; Belem Acevedo; Alexis Pineda; Evelyn Leiva; Paola Pusineri; Sandra Consani; Mariela Zarza; Clyde Parodi; Zoilo Morel; Roger Rolón; Paola Jara; Raquel Aranda; Laura Martínez; Gabriela Ávila;

Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling Akhil Akhil; Rohit Bansal; Jyotsana Kaushal; Aman Sharma; Archana Bhatnagar;